Creatine as a hair growth agent (and its other interesting properties)
Kofi
properties of creatine. Caspase inhibitors have been known to delay
catagen.
<http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2F
netahtml%2FPTO%2Fsearch-adv.html&r=64&f=G&l=50&d=PG01&s1=%22hair+growth%2
2&p=2&OS=baldness&RS=>
[Help] [Home] [Boolean Search] [Manual] [Number Search] [PTDLs]
[PREV_LIST] [CURR_LIST] [NEXT_LIST] [PREV_DOC] [NEXT_DOC]
[Shopping Cart] [Order Copy]
[Image]
( 64 of 1132 )
United States Patent Application 20040171693
Kind Code A1
Gan, David C. ; et al. September 2, 2004
Method for increasing hair growth
Abstract
The present invention provides a method for stimulating hair follicle
growth, which comprises applying a composition containing a follicle
stimulating effective amount of a creatine compound. The method can be
used to treat and prevent conditions such as male pattern baldness, hair
loss due to aging, or hair loss due to chemotherapy or drug exposure.
Inventors: Gan, David C.; (Huntington Sta., NY) ; Hawkins, Geoffrey;
(Penn Valley, PA) ; Mammone, Thomas; (Farmingdale, NY) ; Presti,
Richard; (East Meadow, NY) ; Sparacio, Rose Maire; (Manorville, NY)
Correspondence Name and Address:
THE ESTEE LAUDER COS, INC
ATTN: KAREN A. LOWNEY
125 PINELAWN ROAD
MELVILLE
NY
11747
US
Serial No.: 786847
Series Code: 10
Filed: February 25, 2004
U.S. Current Class: 514/565
U.S. Class at Publication: 514/565
Intern'l Class: A61K 031/198
Claims
What we claim is:
1. A method for increasing the proliferation of dermal papilla cells in
hair follicles which comprises applying to the cells a composition
containing a follicle-stimulating effective amount of a creatine
compound.
[Omitted boilerplate stuff]
FIELD OF THE INVENTION
[0001] The invention relates to the field of personal care. More
specifically, the invention relates to methods for increasing hair
growth and prevention of hair loss.
BACKGROUND OF THE INVENTION
[0002] The quest to find a safe, reliable methodology for treating and
preventing baldness has been ongoing for many years. Although certainly
not life-threatening, the loss of hair, in both men and women, causes
significant distress to the afflicted individual, and can seriously
affect the individual's self-esteem. The problems involved in finding a
safe and effective treatment are many. First, the underlying cause of
the hair loss is not always the same from individual to individual.
Also, the process by which hair grows encompasses several phases and
there are many contributory factors that can alter the normal vigorous
growth of hair. The hair growth cycle is divided into three phases: an
anagen phase, in which the hair is growing actively, with a very
substantial level of cell proliferation occurring in the hair follicle;
a catagen phase, when the follicle slows down its proliferative activity
temporarily to permit hair development; and a telogen phase, in which
the follicle simply stops growing and regresses, until the hair is shed,
and a new anagen phase begins.
[0003] It is of course completely normal for the average person to lose
many hairs on a daily basis, and therefore, this cycle is normally
repeated continually throughout life, to replenish the hair that is
lost. The cycle does slow down with age in all individuals, however with
the normal hairs gradually being replaced by progressively finer hair
(vellus hair), and the cycles becoming shorter. For individuals who
suffer from abnormal hair loss, it is apparent that the normal cyclical
process becomes disrupted in some fashion, whether it be through an
abnormal acceleration or other alteration of the process; this
eventually results in a more rapid shift to the telogen phase, which in
turn gradually results in the production of more vellus hair and
ultimately may result in baldness.
[0004] The causes of this shift to shorter cycles is still not
completely understood. A large number of factors contribute to the
pattern of hair growth, including, but not limited to, diet, drug
exposure, and hormones. A variety of different types have been proposed
over the years for treatment of hair loss; these treatments may attempt
to counteract the effects of the harmful factors, such as hormones, or
they may attempt to directly restimulate the activity in dormant
follicles. Many of the agents that have been shown to be successful in
renewing hair growth are synthetic pharmaceutical agents, such as
minoxidil or procaine. While these materials are effective, they do have
some disadvantages in that, as drugs, they may have undesired systemic
effects, and/or they may have to be administered orally; in many cases,
the treatments are largely targeted to androgenic alopecia, or male
pattern baldness, and therefore may not be safe or effective for use by
female candidates experiencing hair loss. The gold standard for hair
growth enhancers is therefore a natural material that is not hormonal
either in chemical nature or in target, that can be administered
topically without concern to both males and females experiencing hair
loss, and which preferably has a direct effect on stimulation of the
hair follicle itself. Although a number of naturally occurring
materials, such as saw palmetto, have been recommended for use in the
promotion of hair growth, there has been no widespread commercial
success or acceptance of any of the natural remedies for hair loss by
both men and women. There thus continues to be a need for a method of
treating hair loss that utilizes a non-hormonal naturally occurring
material as its active component. The present invention now provides
such a method.
SUMMARY OF THE INVENTION
[0005] The present invention relates to a method for stimulating
proliferative activity in hair follicles which comprises applying to the
hair follicle a follicle-stimulating effective amount of creatine or a
creatine derivative. The invention also relates to a method for treating
or preventing hair loss which comprises applying topically to the hair
and/or scalp a follicle-stimulating effective amount of creatine, or a
creatine derivative. The method of the invention thus utilizes a
naturally occurring material, creatine, that is normally present in
human cells, to increase the level of hair growth in hair follicles.
DETAILED DESCRIPTION OF THE INVENTION
[0006] The present inventors have observed, unexpectedly, that creatine,
when applied to dermal papilla cells, is capable of producing a
significant increase in the level of DNA synthesis of those cells (see
Example 1). Dermal papilla cells are present in the hair follicle, and
have been suggested to be involved in hair growth by modulating the
activity of keratinocyte (matrix cells) proliferation and
differentiation (Shimaoka et al., J. Dermatol. Sci. 7(Suppl): S79-S83,
1994) It was therefore attempted to determine in the increase in DNA
synthesis could be translated into actual increase in hair growth. Again
unexpectedly, the application of creatine, in amounts of as little as 1
mM, is capable of increasing actual hair length in hair plugs relative
to untreated controls by statistically significant levels (see Example
2), thus confirming its efficacy in treating and preventing hair loss.
[0007] Creatine is a naturally-occurring material that is normally
present in various mammalian tissues, such as the heart, skeletal
muscle, brain and retina. It has previously found many therapeutic uses,
for example, in the treatment of glucose metabolic disorders (U.S. Pat.
No. 6,075,031); in the treatment of obesity (U.S. Pat. No. 5,998,457);
and treatment of skin damage (U.S. Pat. No. 6,242,491). It has not
previously, to Applicants' knowledge, been known for use in the
promotion of hair growth. The creatine employed in the present invention
can be naturally derived, i.e., isolated directly from biological
material, or can be obtained synthetically or semi-synthetically. In
addition to creatine per se, the method can also be employed using
creatine derivatives or analogues. Examples of such materials include
but are not limited to, creatine phosphate and cyclocreatine; other
creatine analogues are also known and have been disclosed, for example,
in U.S. Pat. No. 6,075,031, the contents of which are incorporated
herein by reference. As used in the present context, the term "creatine
compound(s)" refers to both creatine and creatine analogues that exhibit
the same type of stimulatory activity. The follicle-stimulating
effective amount employed in the present method is that amount that is
capable of increasing the hair growth of a follicle at least 20% above
the growth observed in an untreated follicle, preferably increasing at
least 40%, more preferably at least 50%, and most preferably at least
80%.
[0008] The creatine compound is used in the form of a topical
formulation for application to the hair and scalp. The composition of
the formulation is not critical, and the vehicle may be any that is
acceptable for topical application, particularly compositions adapted
for application to hair or scalp. The formulation may be applied as a
shampoo, a hair rinse, a conditioner, a pomade, a gel, or any other form
that is normally used for treatment of hair. In a preferred embodiment,
the composition is applied as a shampoo, conditioner or rinse. In
practical terms, the "effective amount" used in a formulation will
generally be from about 0.0001 to about 20%, preferably about 0.001 to
about 10%, more preferably about 0.01 to about 10%, by weight of the
total composition.
[0009] The compositions may contain one or more creatine compounds alone
as active agent, or they may be combined with other active agents that
also exhibit beneficial effects on the hair and scalp. Particular
benefit to hair growth may be achieved with the combination of at least
one additional energy enhancing actives, such as adenosine, ATP, ADP,
AMP, oxaloacetic acid(oxaloacetate), NADH, NADPH, or carnitine, or its
derivatives, such as acetyl carnitine or palmitoyl carnitine, each of
which also may have a beneficial effect on the growth of hair. The
overall amount of energy-inducing compounds used in the composition,
including creatine, will, be from about 0.0001 to about 10% by weight,
preferably about 0.01 to about 5%. Particularly preferred is a
combination of creatine with at least one of 5'-AMP, NADH and carnitine,
and an extremely effective combination occurs with all four components
in the composition.
[0010] The hair growth compositions of the invention may also optionally
include other active components having a beneficial effect on hair
growth. One type of additional active is a 5-alpha reductase inhibitor.
Such compounds are known to assist in promotion of hair growth, and
include, but are not limited to saw palmetto (Serenoa) extract, Emblica
officianalis extract, Beta-glycyrrhetic acid, estradiol, estrone,
progesterone, or azasteroids, such as finasteride or dutasteride. It is
particularly preferred that the reductase inhibitor be naturally
derived. A particularly preferred naturally derived inhibitor is a
refined saw palmetto berry extract, commercially available as Viapure
Sabal from Actives International, Ramsey, N.J. The amount of reductase
inhibitor used will vary depending upon the identity and potency of the
material, but will be in accordance with the known effective ranges for
the material. The amount will generally be in the range of about
0.0001-10%, and for the preferred material, saw palmetto extract, this
amount will preferably be from about 0.001 to about 2%.
[0011] The compositions of the invention can also be improved by the
incorporation of one or more antiinflammatory agents. Examples of useful
antiinflammatory materials include, but are not limited to, luteolin,
amentoflavone, hoelen mushroom extract (Poria cocos), stearyl
glycyrrhetinate and other antiinflammatory glycyrrhizic acid
derivatives, manuka oil, emu oil, echinacea, chamomile (matricaria oil),
scuttelaria extracts, artemisia extracts, gentian extract, soybean
protein, calendula, cayenne, turmeric, white willow, sialyl sugars
(e.g., 3' sialyl lactose) and the like. Total amounts of
antiinflammatory agents in the formulation will ordinarily be in the
range of from about 0.0001 to about 10%.
[0012] It may also be desirable to incorporate into the formulation a
pigmentation enhancer, which, while not contributing directly to hair
growth, will enhance the overall benefit of the product by darkening
lighter, less noticeable hair, such as vellus hair. Examples of useful
pigmentation enhancers are N-acetyl-L-tyrosine, tyrosine, forskolin,
phenylalanine, L-DOPA, methylxanthine, or .alpha.-melanocyte stimulating
hormone. The pigmentation enhancing agents will be used in an amount of
about 0.0001 to about 10%.
[0013] Vasodilation enhancers are also an optional component of the
formulation. Vasodilation has long been associated with an increase in
hair growth, not only on the scalp, but also on any other area of the
skin where hair grows. Thus, use of one or more vasodilation agents can
supplement the activity of the energy-increasing compounds and enhance
the overall efficacy of the formulation. Examples of useful vasodilation
agents include, but are not limited to, arginine, ginseng extracts,
gingko extracts, swertia extracts, calpronium chloride, diphenhydramine
hydrochloride, gamma-oryzanol, prostaglandins, vitamin E derivatives
such as vitamin E nicotinate, pinacidil, minoxidil, phthalides, quina
extracts, Capsicum extracts, orange peel extracts, and citron extracts.
This component, if present, will normally be used in an amount of from
about 0.0001 to about 10%.
[0014] The composition may also benefit by the presence of one or more
antioxidants, which will protect against free radicals that can
contribute to hair loss, as well as protect hair from the drying effects
of the sun and other photodamage. Examples of useful antioxidants
include, but are not limited to ginkgo-biloba, beta carotene, green tea,
ascorbic acid and derivatives thereof such as for example sodium
ascorbyl phosphate and magnesium ascorbyl phosphate, camosic acid
(rosemary), resveratrol and derivatives thereof, N-acetyl cysteine, and
BHT and BHA. The green tea, as well as other antioxidants, can be in the
form of an extract or any other known form of the antioxidant, as well
as the active components of extracts, e.g., catechin based flavonoids
such as EGCG (epigallcatechin gallate) from green tea, rosemary extract,
and the like. Antioxidants, if used, will be present in an amount of
from about 0.0001 to about 10%
[0015] The composition may further comprise one or more cell
differentiation activators. Particularly preferred are extracts of sage,
for example clary sage, and/or any differentiation-active compounds,
such as sclareolide, obtainable therefrom. Other examples of useful
differentiation active compounds are forskolin, 7-dehydrocholesterol,
and Vitamin D3 analogs. A particularly preferred component for this
purpose is a clary sage fermented extract commercially available from
Avoca/RJ Reynolds. Amounts used, if present, will be from about 0.001 to
about 10%, preferably from about 0.01 to about 1%
[0016] The hair growth formulations can also include a firming component
which promotes the support in the basement membrane and dermis to
encourage and support the hair structure. Examples of firming components
are compounds that enhances the amount of collagen and/or elastin in the
skin, for example, collagenase and or elastase inhibitors or collagen or
elastin synthesis enhancers. Such compounds include, but are not limited
to triterpenoid-containing extracts and refined compounds, for example,
white birch bark extract, silver birch bark extract, Boswellia extract,
bearberry extract, Centella asiatica extract, Mimosa tenuiflora bark
extract, or Pygeum (Prunus) africanum extract and individual active
compounds that may be present in these extracts, including
betulinol(betulin), betulinic acid, boswellic acid, ursolic acid,
oleanolic acid, oleanol, asiaticoside, asiatic acid, and madagassic
acid; phenolic-containing extracts, such as green tea extracts and apple
extracts, and compounds contained therein, such as EGCG, ECG, catechins,
phenylpropanoids, and phloretin; and Vitamin C and derivatives thereof
for enhancing collagen synthesis. A preferred collagenase inhibitor is
Mimosa tenuiflora extract known as tepescohuite, and a preferred Vitamin
C derivative is BV-OSV. The firming agents are used in amount of about
0.001 to about 10% by weight of the composition.
[0017] The composition may also contain other non-active materials that
are useful in improving the condition of the hair or scalp, for example,
moisturizers, hair conditioners and detanglers, thickeners, gellants,
film formers, fragrance, and the like. The vehicle in which the active
ingredients are applied can be in any form typically used for
application to the hair, for example, creams, gels, sprays, mousses and
the like. It is generally preferred, however, that the formulation not
be completely aqueous.
[0018] The creatine compound containing composition can be used in a
variety of applications. For example, in one embodiment, the invention
encompasses applying a creatine compound to healthy hair and scalp, to
maintain the normal cycle of hair replacement, and to reduce or prevent
the normal thinning that occurs with age. The compositions of the
invention will also aid in retention of the hair that is already present
on the scalp and also to increase the diameter of hair already present.
In another embodiment, the composition is applied to the hair and scalp
of an individual that is in the early stages of hair loss, or at genetic
risk for baldness, but who are not yet bald, so as to prevent or slow
down the hair loss, maintaining hair growth in healthy follicles, and
restoring growth of follicles that may have already become substantially
inactive. Restoration of overplucked or thinning eyebrows, which shall
be understood to be encompassed in the word "hair" herein, is also
possible. Finally, the method may be applied to individuals experiencing
alopecia, so as to reverse the balding and reinstitute normal hair
growth in existing follicles. As already noted, this methodology can be
applied effectively to both males and females, and can be used
regardless of the ultimate cause of the hair loss, i.e., whether it is
male pattern baldness, the thinning naturally experienced due to age, or
hair loss resulting from chemotherapy or other drug exposure. Although
not essential for results, optimum hair growth will occur with a
frequency of application of at least three to five times a week, and
daily use of the creatine containing composition is particularly
recommended during the time period of treatment. The timing of its usage
will be determined according to the cause of the hair loss; a temporary
hair loss, due for example to drug exposure, may require only regular
use on a temporary basis, until after the removal of the harmful
stimulus and subsequent regrowth of hair to a satisfactory level.
However, for pattern or age-related baldness or thinning hair, where the
causative agent is a constant presence, a chronic application is
preferred, i.e., the application will be regularly applied over the
lifetime of the user, it is meant herein that the period of topical
application may be over the lifetime of the user, preferably for a
period of at least about one month, more preferably from about three
months to about twenty years, more preferably from about six months to
about ten years, more preferably still from about one year to about five
years, or for as long as the user is interested in maintaining his or
her hair growth. The amount of product applied will vary according to
the form of the product, but will normally be in accordance with the
industry accepted methodology for the use of a product of the same type.
A representative application procedure will involve application of the
formulation to the area in need of treatment once or twice a day, and
leaving the formulation in place for a period of several hours. The
invention is further illustrated by the following non-limiting examples.
EXAMPLE 1
[0019] This example illustrates the increase in proliferation of dermal
papillae when exposed to creatine.
[0020] Methods: Normal Human Dermal Papilla Cells were obtained from
Cell Applications Incorporated (San Diego, Calif.) which isolates the
dermal papilla cells from hair plugs. Papilla cells were grown to 70% in
24 well plates. These cells were treated with dosages of creatine
(Sigma) ranging from 0.25-1 mM Creatine (Sigma), and 0.25-0.5 mM
Oxaloacetate (Sigma). These treatments were carried out for 24 hours
before [H]3-Thymidine label (1 .mu.Ci/ml) was added in each well. DNA
synthesis, an indicator of cell proliferation, was measured 24 hours
later as a function of [H].sup.3-Thymidine incorporation.
[0021] Results: Creatine was found to significantly increase DNA
synthesis in papilla cells (see Tables 1&2). At 0.25 mM, creatine
induced a 36% increase in DNA synthesis. At 0.5 mM, creatine induced a
25% increase in DNA synthesis. At 1 mM, creatine induced a 6% increase
in DNA synthesis. Oxaloacetate was also found to significantly increase
DNA synthesis in papilla cells in a dose dependent manner. At 0.25 mM,
Oxaloacetate induced a 22% increase in DNA synthesis. At 0.5 mM,
Oxaloacetate induced a 33% increase in DNA synthesis. At 1 mM,
Oxaloacetate induced a 38% increase in DNA synthesis. Positive results
have also been observed with equivalent concentrations of AMP(1493%
increase at 0.25 mM, 1930% at 0.5 mM, 1449% at 1 mM) and ATP(1411%
increase at 0.25 mM, 1201% at 0.5 mM).
[0022] Discussion: Each of the energy enhancing substrates creatine,
AMP, oxaloacetate and ATP were found to increase DNA synthesis in the
dermal papilla cells. This increase was statistically significant.
1TABLE 1 .sup.3+ [H] counts to denote incorporated Thymidine (relative
DNA synthesis) 0.25 0.5 1 mM Oxal 26907.8 24483.7 25537.3 21897.4
21467.8 25092.4 19022.9 28397.4 26130.3 Creatine 23398.7 24738.6 19992.4
27441.5 21850.6 20190.6 24848.2 23029.9 18789.8
[0023]
2TABLE 2 Summary of percentage increase in uptake thymidine uptake in
various treatments % increase compared Average St.dev. to control
Control 18598.12 1696.271 Creatine 25229.47 2048.19 35.65601 0.25 mM
Creatine 23206.37 1452.065 24.77802 0.5 mM Creatine 19657.6 758.0425
5.696705 1 mM Oxal 22609.37 3990.374 21.56802 0.25 mM Oxal 24782.97
3474.48 33.25523 0.5 mM Oxal 25586.67 520.7081 37.57663 1 mM
Example 2
[0024] This example illustrates the increase in hair growth observed in
hair plugs exposed to creatine.
[0025] Methods: Hair plugs were obtained from East Wood Medical Hair
Transplant Surgery (Garden City, N.Y.). These hair plugs were
equilibrated in hair plug media as described in the literature (DMEM,
10% FBS, 1% PS, 25 mg insulin, 25 .mu.g fungizone). These hair plugs
were measured under the microscope one the first day of arrival and
treated with creatine at 1 mM (n=6 for control and creatine group
respectively). These hair plugs were then kept in the incubator at
37.degree. C. in 5% CO.sub.2. On day 3, 7, & 10, re-treatments were made
as well as measurements.
[0026] Results: The hair plugs were found to grow at a constant rate. In
the untreated group, there was an average growth of 0.48 mm at day 3
compared to day 0. There was an average growth of 0.73 mm at day 7, and
an average growth of 0.82 mm at day 10. Creatine was found to
significantly increase the growth rate of these hair plugs compared to
the untreated plugs. There was an average growth of 0.95 mm at day 3,
1.32 mm at day 7, and 1.43 mm at day 10 (Refer to Table 3, 4, and 5).
These increases were all statistically significant.
[0027] Discussion: Creatine was found to significantly increase hair
growth in hair plugs. This increase was nearly two fold compared to the
untreated plugs. We previously observed creatine increasing DNA
synthesis in dermal papilla cells. As dermal papilla cells influence and
modulate the growth of hair, we postulate that creatine may be
increasing hair plug growth by increasing the activity of dermal papilla
cells.
3TABLE 3 Actual length of hair plugs (mm) over 10 days mm Day 0 Day 3
Day 7 Day 10 Control 7.8 8.2 8.6 8.9 Control 6 6.6 6.7 6.9 Control 6.7
7.3 7.6 7.6 Control 7.3 7.6 7.9 7.8 Control 5 5.1 5.4 5.6 Control 6.7
7.6 7.7 7.6 Creatine 3.8 4.7 5 5.5 Creatine 6.3 7.1 7 7 Creatine 8.1 9.5
9.6 9.7 Creatine 8.3 9.1 9.6 9.7 Creatine 8.2 9.1 9.8 9.8 Creatine 7.6
8.5 9.2 9.2
[0028]
4TABLE 4 Hair growth normalized to length at day 0. Mm Day 3 Day 7 Day
10 Control 0.4 0.8 1.1 Control 0.6 0.7 0.9 Control 0.6 0.9 0.9 Control
0.3 0.6 0.5 Control 0.1 0.4 0.6 Control 0.9 1 0.9 Creatine 0.9 1.2 1.7
Creatine 0.8 0.7 0.7 Creatine 1.4 1.5 1.6 Creatine 0.8 1.3 1.4 Creatine
0.9 1.6 1.6 Creatine 0.9 1.6 1.6
[0029]
5TABLE 5 Average hair growth over 10 days in untreated and creatine
treated hair plugs average 0 3 7 10 Day Control 0 0.483333 0.733333
0.816667 Creatine (1 mM) 0 0.95 1.316667 1.433333 st.dev. 0 3 7 10 Day 0
0.278687 0.216025 0.22286 0 0.225832 0.343026 0.37238 3 7 10 Day %
increase compared 96.6 79.5 75.5 to untreated p = value 0.016086
0.014825 0.016493
EXAMPLE 3
[0030] This example illustrates the activity of a blend of energy
enhancing compounds in promoting hair growth.
[0031] Methods: Hair plugs were obtained from East Wood Medical Hair
Transplant Surgery (Garden City, N.Y.). These hair plugs were
equilibrated in hair plug media as described in the literature (DMEM,
10% BCS, 1% PS, 25 .quadrature.g fungizone). Hair plug measurements were
taken on the first day (Day 0). Hair plugs were treated with 0, 0.01,
0.1, and 1.times.of the energy blend. 1.times. of Energy blend
corresponds to AMP at 0.25 mM, creatine at 2.5 mM, L-carnitine at 2 mM,
and NADH at 2 mM. After 4 days, measurements were made again before
re-treatments with fresh media with their respective concentrations
(n=12 for control and treated groups respectively). These hair plugs
were kept in the incubator at 37.degree. C. in 5% CO.sub.2. Measurements
and re-treatments were made again 3 days after. Hair plug growth was
measured by comparing lengths at day 4, day 7, day 12, and day 14
compared to day 0. On day 14, representative hair plugs from the
different treatment groups were labeled with BRDU. These hair plugs were
then sent to Paragon Biotechnology for histological sections. BRDU
labeling of active proliferating cells were assessed.
[0032] Results: The hair plugs were found to grow at a constant rate. In
untreated hair plugs, the average increase in hair length at day 4, 6,
10, and 14 compared to day 0 was 0.11, 0.16, 0.2, 0.26 mm 1). In hair
plugs treated with the energy blend at 0.01.times., the average increase
in hair length at day 4, 6, 10, and 14 compared to day 0 was 0.24, 0.33,
0.41, 0.47 mm. In hair plugs treated the energy blend at 0.1.times., the
average increase in hair length at day 4, 6, 10, and 14 compared to day
0 was 0.41, 0.54, 0.54, 0.64 mm. In hair plugs treated with the energy
blend at 1.times., the average increase in hair length at day 4, 6, 10,
and 14 compared to day 0 was 0.21, 0.28, 0.35, 0.49 mm. Hair plug growth
increased as much as 268% at 0.1.times.treatments of the energy blend,
116% at 0.01.times.treatments of the energy blend, and 87% at
1.times.treatments of the energy blend. In addition, immunohistologies
of the hair bulb revealed that there were more actively proliferating
cells in the energy blend treated hair plug than the untreated control.
[0033] Discussion: The energy blend treatment containing AMP, creatine,
L-carnitine, and NADH, was found to increase hair plug growth. This
treatment blend was found to be optimal with AMP at 0.025 mM, creatine
at 0.25 mM, L-carnitine at 0.2 mM, and NADH at 0.2 mM. Hair plug growth
up to 268% was observed compared to untreated control after 4 days. In
addition, BRDU labeling also revealed more actively proliferating cells
in the hair bulb of hair plugs treated with the energy blend. The
treatment blend at concentrations 10.times.higher than the previously
mentioned concentration was not as effective in increasing hair growth
(87%). This may be due to over-saturation or lowered pH due to carnitine
and NADH.
[0034] It is hypothesized that the observed increase in hair growth is
partly due to the increase in dermal papilla cell activity and growth
factor release. Previously, we have observed increased DNA synthesis in
dermal papilla cells treated with the energy technology.
6TABLE 6 Increase in hair plug growth compared to day 0 (mm) & %
increase in hair growth compared to untreated. 1X of Energy blend
corresponds to AMP at 0.25 mM, creatine at 2.5 mM, L-carnitine at 2 mM,
and NADH at 2 mM. day 0 4 6 10 14 Control 0 0.1125 0.1625 0.2 0.2625
Energy blend (.01X) 0 0.242857 0.328571 0.414286 0.471429 Energy blend
(.1X) 0 0.414286 0.542857 0.542857 0.642857 Energy blend (1X) 0 0.21
0.275 0.35 0.49 day % change compared to Control 4 6 10 14 Energy blend
(.01X) 115.87 103.77 107.14 79.59 Energy blend (.1X) 268.25 236.66
171.43 144.90 Energy blend (1X) 86.67 70.54 75.00 86.67
EXAMPLE 4
[0035] This example illustrates compositions of the present invention.
All amounts are percent by weight of the total composition.
7 Composition Composition Material Composition A B C Sorbic acid 0.15
Water/Disodium EDTA- 0.10 copper Amentoflavone 0.10 Nicotinamide
adenosine 0.10 dinucleotide Luteolin monohydrate 0.10 Mimosa tenuiflora
bark 0.05 extract Arginine 0.20 Tocopherol nicotinate 0.20 0.20 Gentian
extract 0.20 Dipotassium glycyrrhizate 0.1 0.1 Adenosine phosphate 0.1
1.00 Camphor 0.05 Cholesterol/potassium 0.05 sulfate Capsicum frutescens
fruit 0.02 extract Butylene glycol 0.01 Flavor 0.0025 D&C Violet No. 2
0.00005 Cyclomethicone 10.00 Glycerin 2.00 Hydrogenated lecithin 2.00
Sorbitol 2.00 Sodium stearoyl glutamate 2.00 C12-15 alkyl benzoate 2.00
Dimethyl isosorbide 2.00 Oleic acid 1.00 Dimethicone 1.00 Steareth-10
allyl 1.00 ether/acrylates Phenoxyethanol 0.80 N-acetyl tyrosine 0.50
Emblica officianalis fruit 0.25 extract Tetrahydrodecyl ascorbate 0.20
Gingko biloba extract 0.20 Acetyl camitine HCl 0.20 Panthenol 0.20 0.20
Denatured alcohol 57.20 68.9725 Purified water 36.22 24.36995 69.10
Isoceteth-20 1.50 0.50 PPG-28-Buteth-35 1.00 0.50 Declustered water 0.60
Acetyl glucosamine 0.55 0.50 Menthol 0.50 Fragrance 0.50 Declustered
water 0.40 PEG-25 soya sterol 0.25 0.125 Hydroxypropyl cellulose 0.20
Adenosine phosphate 0.11 Glycyrrhiza glabra 0.11 (licorice) extract
Butylene glycol/water/hops 0.10 0.50 extract Caffeine 0.10 0.20
Water/butylene glycol/ 0.10 Laminaria Yeast extract 0.10 1.00 Creatine
1.00 1.00 Saccharomyces lysate 0.10 0.10 0.20 extract/water Serenoa
serrulata fruit 0.10 0.10 extract Salvia sclarea (clary) 0.10 0.10
extract Octyl methoxycinnamate 0.01 Betula alba extract 0.01 Poria cocos
extract 0.01 0.05 Yeast extract/Centella 0.01 2.00 asiatica Algae
extract 0.01 Octyl salicylate 0.01 PEG/PPG-20/15 0.30 dimethicone
* * * * *
[Image]
[Order Copy] Shopping Cart [PREV_LIST] [CURR_LIST] [NEXT_LIST]
[PREV_DOC] [NEXT_DOC]
[Help] [Home] [Boolean Search] [Manual] [Number Search] [PTDLs]
Ernie Primeau
Ernie Primeau
If I knew the cause of hair loss, I would not be still in here being a
prick.Ernie
Smee
> If I knew the cause of hair loss, I would not be in here.Ernie
Very true Ernball!